# Semaglutide: Research Overview — Booking Peptides > A literature summary of semaglutide: mechanism, STEP/SELECT/FLOW/SUSTAIN-6 trial data, real-world reports, and safety cautions from the peer-reviewed record. No medical advice. A long-acting GLP-1 receptor agonist with the broadest human evidence base on this desk — and a safety profile that is more nuanced than its reputation suggests. ## The short version Semaglutide is a synthetic version of a hormone your gut naturally releases after eating. That hormone — GLP-1 — tells the pancreas to produce insulin and tells the brain you are full. Semaglutide does the same thing, but it is engineered to stay in the body for roughly a week instead of two minutes. The result: sustained appetite suppression, slower gastric emptying, and better glucose control. The human evidence here is substantial. Large randomized controlled trials found mean body-weight losses around 15% in people with obesity [4], reduced cardiovascular events in people with established heart disease [3], and reduced kidney-disease events in people with type 2 diabetes and chronic kidney disease [2]. Semaglutide is an FDA-approved prescription medicine for type 2 diabetes, chronic weight management, and cardiovascular risk reduction. It is not a supplement and not available over the counter. This page reports what the studies found; it does not recommend any dose or use. ## What it is Semaglutide is a 31-amino-acid acylated analogue of human GLP-1, sharing approximately 94% sequence homology with the native hormone. Two structural modifications extend its half-life: an alanine-to-Aib substitution at position 8 blocks cleavage by DPP-4 (the enzyme that degrades native GLP-1 in about two minutes), and a C18 fatty di-acid side chain attached via a glutamic-acid/ADO spacer drives tight, reversible binding to serum albumin, which protects it from renal clearance. The combined result is a half-life of roughly one week — the basis for once-weekly dosing. It is approved as a subcutaneous injection and, separately, as an oral tablet. The oral formulation is co-formulated with SNAC, an absorption enhancer, and its bioavailability is approximately 0.4–1%. ## How it works By activating the GLP-1 receptor, semaglutide does several things at once: **Pancreatic effects.** It potentiates glucose-dependent insulin secretion from beta cells and suppresses inappropriate glucagon release from alpha cells — effects that are dependent on ambient glucose, which limits hypoglycemia risk in isolation. **Gastric effects.** It slows gastric emptying, contributing to satiety and partly accounting for the nausea that is the dominant early side effect. **Central appetite effects.** This is the primary driver of its weight effect. In rodent studies, semaglutide accessed the brainstem, area postrema, hypothalamic arcuate nucleus, and parabrachial nucleus — appetite circuits — activating anorexigenic neurons and inhibiting hunger-promoting ones, reducing food intake and modifying food preference [6]. People often describe this as the "food noise" quieting. **Cardiovascular and renal effects.** GLP-1 receptors are expressed on cardiac and renal tissue; their agonism contributes to pleiotropic protective effects documented in large outcomes trials [2][3][7]. ## What the research shows *Weight management (STEP 1).* In the STEP 1 randomized controlled trial (n=1,961 adults with overweight or obesity, no diabetes), once-weekly subcutaneous semaglutide 2.4 mg produced a mean body-weight change of -14.9% at 68 weeks versus -2.4% with placebo [4]. This is the cornerstone efficacy finding. *Head-to-head versus tirzepatide (SURMOUNT-5).* When semaglutide was compared directly against tirzepatide in 751 adults with obesity, semaglutide produced -13.7% weight loss versus -20.2% with tirzepatide at 72 weeks (P<0.001) [1]. Tirzepatide was superior; semaglutide was not ineffective. *Cardiovascular outcomes (SELECT).* In the SELECT trial (n=17,604 adults with preexisting cardiovascular disease and overweight or obesity but no diabetes), semaglutide 2.4 mg reduced major adverse cardiovascular events versus placebo — HR 0.80 (95% CI 0.72–0.90; P<0.001) — a 20% relative risk reduction [3]. *Kidney outcomes (FLOW).* In the FLOW trial (n=3,533 adults with type 2 diabetes and chronic kidney disease), semaglutide 1.0 mg reduced the composite of kidney failure, ≥50% eGFR decline, or kidney/cardiovascular death — HR 0.76 (95% CI 0.66–0.88) [2]. *Early cardiovascular data (SUSTAIN-6).* In 3,297 adults with type 2 diabetes at high cardiovascular risk, once-weekly semaglutide 0.5 or 1.0 mg reduced the primary MACE composite (HR 0.74; 95% CI 0.58–0.95) but raised diabetic-retinopathy complication rates among patients with pre-existing retinopathy undergoing rapid glycemic correction (HR 1.76; 95% CI 1.11–2.78) [7]. *Safety profile (review).* A dedicated safety assessment concluded that semaglutide has an overall favorable risk/benefit profile, with mild-to-moderate transient gastrointestinal effects as the dominant adverse event (nausea in roughly one-third of patients), increased biliary disease risk, and unconfirmed pancreatic and thyroid-cancer signals owing to low incidence [5]. *Central mechanism (rodent).* Mechanistic work showed semaglutide reduces body weight in rodents through distributed CNS pathways, directly accessing brainstem and hypothalamic circuits and reducing food intake without lowering energy expenditure [6]. ## Reported effects, cautions & safety **Community-reported effects (anecdotal, not clinical evidence).** People taking semaglutide consistently describe appetite suppression as the defining experience — what they call "food noise" going quiet. The constant background preoccupation with food fades, portion sizes drop to a third or half of prior intake, and cravings for sweets and fried foods diminish or disappear, sometimes within the first two weeks. Weight loss follows — steady and substantial over months, tied directly to eating much less. Some report blood-sugar readings improving markedly. An occasionally reported secondary effect is reduced interest in alcohol alongside the food-craving reduction. On the side-effect side, nausea is by far the most common complaint, mentioned by roughly a third of people and often worst around dose increases; it typically eases within one to two weeks of a new dose. Foul-smelling "sulfur burps" come up repeatedly. Bowel changes — constipation and diarrhea, sometimes alternating — are common. Fatigue in the day or two after injection is frequently mentioned, especially early. A smaller group reports headaches, injection-site reactions, acid reflux, food aversions, and hair shedding (usually attributed to rapid weight loss rather than the drug itself). All of the above is anecdotal, self-reported, and unverified. **Safety cautions from the literature.** - *Gastrointestinal intolerance:* Nausea, vomiting, diarrhea, and constipation dominate the adverse-effect profile in trials and are the main reason people discontinue [5]. - *Boxed warning — thyroid C-cell tumors:* Rodent studies found C-cell tumors at supratherapeutic exposures; no clear human signal established, but the drug is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN-2 [5]. - *Acute pancreatitis (class warning):* Treatment is stopped if pancreatitis is suspected; no confirmed increase in pancreatic cancer in trials [5]. - *Gallbladder disease:* Increased cholelithiasis risk documented, attributed largely to the rate and magnitude of weight loss [5]. - *Diabetic retinopathy:* In SUSTAIN-6, retinopathy complications were higher in patients with pre-existing retinopathy undergoing rapid glycemic correction (HR 1.76) [7][5]. - *Lean-mass loss:* Body-composition substudies show a meaningful fraction of weight lost is lean mass, raising sarcopenia concerns [5]. - *Weight regain after stopping:* STEP 1 extension and STEP 4 data show substantial regain after discontinuation — framing this as a chronic, not curative, intervention [5]. - *Pregnancy:* Contraindicated; the approximately one-week half-life means discontinuing well before a planned conception is advised. - *Drug interactions:* Delayed gastric emptying can affect absorption of co-administered narrow-therapeutic-index oral drugs [5]. ## Where it fits Semaglutide is the most-studied compound on this desk and the one with the broadest regulatory approval. Its cardiovascular and kidney-outcome trial data extend well beyond weight loss into meaningful disease endpoints. Within this hub's metabolic theme, it is the reference point — the compound against which tirzepatide demonstrated superiority [1] and against which retatrutide's investigational profile is measured. Read alongside [tirzepatide](/tirzepatide) (dual agonist) and [retatrutide](/retatrutide) (triple agonist) to see how each additional receptor target shifts the efficacy and safety picture. See the [comparison page](/compare) for a side-by-side. ![Semaglutide incretin pathway research illustration](/images/semaglutide.webp) --- A literature digest — what the studies found, in the species studied, stated plainly and stopped.